Christina Ackermann - 25 Jul 2022 Form 4 Insider Report for Bausch & Lomb Corp (BLCO)

Role
Officer
Signature
/s/ Debra E. Levin, attorney-in-fact
Issuer symbol
BLCO
Transactions as of
25 Jul 2022
Net transactions value
$0
Form type
4
Filing time
27 Jul 2022, 19:38:03 UTC
Previous filing
03 Jun 2022
Next filing
03 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLCO Common Shares, No Par Value Award $0 +35,000 +42% $0.000000 118,333 25 Jul 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the "Plan") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch + Lomb Corporation.

Remarks:

The Reporting Person's title as an officer of the Issuer is Executive Vice President & General Counsel and President, Ophthalmic Pharmaceuticals.